WW International, Inc. Overview
Pro stress-test →WW International provides weight management products and services globally, offering nutritional, activity, behavioral, and lifestyle tools for individual weight goals, as well as for people taking GLP-1 medications or living with diabetes, and guidance for perimenopause and menopause. The company provides a doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support.
Strategic Profile
Pro stress-test →The company reported 2.7 million total subscribers and 197,000 clinical subscribers as of Q1 2026, with clinical subscription revenue up 32% year-over-year to $39 million. WW added FDA-approved Ozempic pill (semaglutide) to its Med+ formulary effective May 1, 2026, and announced plans to offer Eli Lilly's Foundayo (orforglipron) effective April 9, 2026, reflecting a strategic pivot toward higher-margin clinical and premium subscription tiers.
Competitive Landscape
Pro stress-test →WW competes in the digital weight management and clinical weight-loss markets against direct competitors like Noom and Calibrate, as well as broader wellness platforms like MyFitnessPal. The market is increasingly competitive due to GLP-1 medication availability through telehealth competitors and traditional healthcare providers. WW's differentiation lies in its historical brand equity, Points Program, and ability to integrate behavioral support with clinical GLP-1 access through its Med+ tier.
Industry Context
WW International, Inc. operates in Digital weight management and clinical weight-loss platforms.
Key facts
Founded: 1963 · Headquarters: New York City, US · Employees: 3,500 · Revenue: $168M (Q1 2026); FY2026 guidance $620–$635M · Market cap: $175–$183M